Anti-CD20 monoclonal antibodies(BASF Corp.)(Anti-CD20 monoclonal antibodies(BASF Corp.))

概要

基本信息

药物类型

单克隆抗体

别名-

靶点

CD20

作用方式

抑制剂

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症-

非在研适应症

非霍奇金淋巴瘤

原研机构

BASF Corp.

在研机构-

非在研机构

BASF SE

MMRGlobal, Inc.

权益机构-

最高研发阶段无进展临床阶段不明

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Anti-CD20 monoclonal antibodies(BASF Corp.) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD20 monoclonal antibodies(BASF Corp.) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD20 monoclonal antibodies(BASF Corp.) 相关的专利（医药）

登录后查看更多信息

385

项与 Anti-CD20 monoclonal antibodies(BASF Corp.) 相关的文献（医药）

2026-02-01·JOURNAL OF INTERNAL MEDICINE

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management

Review

作者: Visentini, Marcella ; Zignego, Anna Linda ; Ferri, Clodoveo ; Gragnani, Laura ; Arcaini, Luca ; Mazzaro, Cesare ; Gattei, Valter ; Bomben, Riccardo

Abstract:

Cryoglobulinemia (CG) is defined by the presence of serum immunoglobulins that precipitate below 37°C and redissolve upon rewarming. It is classified into three types based on immunoglobulin composition. Type I, a rare form, involves monoclonal IgM or IgG and is linked to lymphoproliferative disorders. Types II and III are known as mixed CG (MC): Type II consists of polyclonal IgG and monoclonal IgM with rheumatoid factor (RF) activity, whereas Type III includes polyclonal IgG and polyclonal IgM with RF activity. MC is predominantly associated with hepatitis C virus (HCV) infection and involves B‐cell lymphoproliferation and autoantibody production. CG may lead to systemic vasculopathy, ranging from mild symptoms (purpura, asthenia, and arthralgia) to severe complications such as skin ulcers, peripheral neuropathy, renal involvement, and non‐Hodgkin lymphoma. Compared to MC, Type I is more often marked by severe cutaneous involvement (ulcers, gangrene), hyperviscosity, and a higher risk of morbidity due to the underlying hematologic malignancy. Management of Type I requires control of vasculopathy and treatment of the hematologic neoplasm, whereas MC demands antiviral therapy in all HCV‐associated or hepatitis B virus–associated cases. Severe vasculopathy in both types may benefit from corticosteroids, immunomodulators, anti‐CD20 monoclonal antibodies, and plasma exchange. A multidisciplinary approach is essential for addressing both etiology and complications, thereby improving outcomes. This review summarizes the pathophysiology, clinical features, recent etiopathogenetic insights, and therapeutic advances related to the various forms of CG.

2026-02-01·Multiple Sclerosis and Related Disorders

Hypogammaglobulinemia and infection risks in multiple sclerosis patients receiving anti-CD20 monoclonal antibodies: Incidence, clinical implications, and longitudinal insights from a three-year Iranian cohort

Article

作者: Moghaddam, Nahid Beladi ; Emami, Ali ; Fallah, Elham Asl ; Paybast, Sepideh ; Ghaffari, Mehran ; Meshkini, Fatemeh

INTRODUCTION:

Anti-CD20 monoclonal antibodies are regarded as high efficacy disease-modifying therapy (DMT) for management of multiple sclerosis (MS). However, prolonged B-cell depletion might increase the risk of secondary hypogammaglobulinemia (SHG) and serious infections. Herein, we aimed to investigate the incidence, severity, and clinical correlates of SHG in MS patients receiving rituximab and ocrelizumab.

METHODS AND MATERIALS:

Between January 2018 and February 2023, MS patients prescribed rituximab and ocrelizumab at Imam Hossein MS Center in Tehran, Iran, were identified. Clinician-reported data were retrospectively collected.

RESULTS:

254 patients were enrolled. The majority (73.2 %) were female with a mean age of 41.22 ± 9.79 and a mean disease duration of 9.79 ± 5.46 years. Mean IgG levels declined from 1108.6 ± 205.6 mg/dL at baseline to 880.7 ± 199.9 mg/dL after three years. Over a mean follow-up of 44.43 ± 15.95 months, 48 patients (18.9 %) developed SHG (IgG < 700 mg/dL), mostly asymptomatic (70.80 %) and mild (85.4 %). SHG was independently associated with lower baseline IgG levels (OR = 0.99 per unit increase; P = 0.001) and a standard interval dosing (SID) regimen (OR = 0.027, 95 % CI: 0.001-1.013, P = 0.051) in subgroup rituximab-treated patients. Serious infections occurred in 7.1 % of patients and were predicted by lower year-one IgG levels (OR = 0.98 per unit increase; P < 0.001).

CONCLUSION:

Our results revealed an 18.9 % incidence rate of SHG in MS patients treated with anti-rituximab and ocrelizumab, which was mainly asymptomatic and mild. We also demonstrated the lower baseline IgG levels and SID regimen as a risk factor to develop SHG. The incidence of SHG at year one was strongly associated with an increased risk of infection. Our findings underscore the IgG monitoring before and during anti-CD20 treatment, along with patient-tailored anti-CD20 regimens to mitigate the risk of SHG and infection.

2026-01-01·Multiple Sclerosis and Related Disorders

Effectiveness of rituximab in the treatment of multiple sclerosis: A multicenter, retrospective, observational study in morocco

Article

作者: Chraa, Mohamed ; Oumerzouk, Jawad ; Hafidi, Jawad ; Abdellaoui, Mohamed ; Bourazza, Ahmed

INTRODUCTION:

The demonstration of the strong efficacy of selective B-cell-depleting therapies, such as anti-CD20 monoclonal antibodies in multiple sclerosis (MS), point out the key role of B cells in triggering MS disease activity.

OBJECTIVE:

To investigate the effectiveness and safety of rituximab (RTX) in MS.

MATERIALS AND METHODS:

We report a retrospective observational study to describe the effectiveness of off-label Rituximab (RTX) in the treatment of a population of 93 Moroccan MS patients including 66 (71 %) relapsing-remitting multiple sclerosis (RRMS) and 27 (29 %) progressive forms of multiple sclerosis (PMS).

RESULTS:

Our study showed that the RTX treatment was associated with the mean ARR decreasing by 71.5 % (p < 0.001) with respect to the previous year and the majority of relapses (62.5 %) occurred within 6 months of starting treatment. The mean EDSS score of the overall patient cohort fell from 4.9 to 4.1 (p = 0.039) after 1 year of treatment with RTX and remained stable in the second year of therapy. EDSS scores improved (CID) after 1 year of treatment with RTX by a score of 0.5-1.0 in 43 (46.2 %) patients and remained stable in the following two years of therapy. Moreover, there was no evidence of disease activity measured by NEDA-3 in 74.2 % of the total sample up to their last follow-up, i.e., 53 (80.3 % ) of RRMS patients and 17 (62.9) % of PMS patients, and there was also a reduction in the number of GEL from 2.3 to 0.2 (p < 0.001). Finally, RTX was discontinued in 7 (7.5 %) patients (4 SPMS, 3 PPMS) and the confirmed worsening of disability (CWD) was the reason for withdrawal.

CONCLUSION:

Off-label RTX treatment should be considered as a therapeutic option for RRMS and some PMS patients, given its efficacy and safety profile with faster onset of action, long duration of action and favorable cost-effectiveness profile.

100 项与 Anti-CD20 monoclonal antibodies(BASF Corp.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非霍奇金淋巴瘤	临床阶段不明	-	MMRGlobal, Inc.	-
非霍奇金淋巴瘤	临床阶段不明	-	BASF SE	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ECTRIMS2022	N/A	多发性硬化症 anti-CD20 monoclonal antibodies	229	Ocrelizumab	願廠鹽齋鏇廠窪齋獵鬱(憲窪鹽齋廠鑰糧鑰選糧) = The most frequent year 1 adverse event were COVID-19 (n=5) 遞壓襯艱簾製願夢簾膚 (顧襯蓋構製衊選範襯鬱 ) 更多	积极	2022-10-12
UK TTP Registry (ISTH2022)	N/A	获得性血栓性血小板减少性紫癜 ADAMTS13	443	Rituximab	願醖糧衊衊膚範襯選鹽(構選餘遞襯鑰選製憲壓) = 壓艱觸餘壓獵蓋網窪願壓獵艱廠繭鏇網艱齋襯 (鏇築壓觸窪構鏇遞繭築 ) 更多	-	2022-07-09
UK TTP Registry (ISTH2022)	N/A	获得性血栓性血小板减少性紫癜 ADAMTS13	443	Obinutuzimab	窪壓繭觸選淵淵繭襯鏇(製膚餘憲膚範鹹餘廠餘) = 襯醖顧選齋窪遞糧構鏇積襯構鏇願遞構夢觸蓋 (鬱憲網鬱衊鹽衊壓遞積 )	-	2022-07-09